Is SCPS or BTI a better dividend investment in 2026?

SCPS currently yields 500000.00% with a 5% 5-year dividend growth rate. BTI yields 5.38% with 5% growth. The better choice depends on your goal: SCPS offers higher current income.

What is the dividend yield difference between SCPS and BTI?

SCPS has a forward dividend yield of 500000.00% ($2.00/share annually). BTI yields 5.38% ($3.15/share annually). The yield gap is 499994.62 percentage points.

Home › Compare › SCPS vs BTI

SCPS vs BTI: Dividend Comparison 2026

SCPS yields 500000.00% · BTI yields 5.38%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SCPS wins by $4.663521010693878e+33M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SCPS

● Live price

500000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.663521010693878e+33M

Annual income

$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00

Full SCPS calculator →

BTI

● Live price

5.38%

Share price

$58.47

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.7K

Annual income

$2,786.64

Full BTI calculator →

Portfolio growth — SCPS vs BTI

📍 SCPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SCPS	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SCPS + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SCPS pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCPS

Annual income on $10K today (after 15% tax)

$42,500,000.00/yr

After 10yr DRIP, annual income (after tax)

$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr

BTI

Annual income on $10K today (after 15% tax)

$457.40/yr

After 10yr DRIP, annual income (after tax)

$2,368.64/yr

At 15% tax rate, SCPS beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCPS + BTI for your $10,000?

SCPS: 50%BTI: 50%

100% BTI50/50100% SCPS

Portfolio after 10yr

$2.331760505346939e+33M

Annual income

$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.96%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SCPS

No analyst data

Altman Z

-250.9

Piotroski

1/9

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.6% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCPS buys

BTI buys

No recent congressional trades found for SCPS or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSCPSBTI

Forward yield	500000.00% ✓	5.38%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$4.663521010693878e+33M	$37.7K ✓
Annual income after 10y	$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00 ✓	$2,786.64
Total dividends collected	$4.6634009849658873e+33M	$14.3K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples

Year-by-year: SCPS vs BTI ($10,000, DRIP)

Year	SCPS Portfolio	SCPS Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$50,010,700	$50,000,000.00	$11,299	$598.92	+$50.00M → SCPS
2	$233,748,371,262	$233,694,859,813.08	$12,794	$703.91	+$233748.36M → SCPS
3	$1,021,074,511,412,696	$1,020,824,400,655,446.10	$14,518	$829.07	+$1021074511.40M → SCPS
4	$4,168,597,328,794,951,700	$4,167,504,779,067,739,000.00	$16,513	$978.64	+$4168597328794.94M → SCPS
5	$15,905,475,114,600,665,000,000	$15,901,014,715,458,854,000,000.00	$18,827	$1,157.84	+$15905475114600664.00M → SCPS
6	$56,718,938,532,531,060,000,000,000	$56,701,919,674,158,435,000,000,000.00	$21,518	$1,373.12	+$56718938532531060736.00M → SCPS
7	$189,031,807,435,623,860,000,000,000,000	$188,971,118,171,394,040,000,000,000,000.00	$24,657	$1,632.46	+$1.8903180743562385e+23M → SCPS
8	$588,799,810,476,518,260,000,000,000,000,000	$588,597,546,442,562,100,000,000,000,000,000.00	$28,329	$1,945.74	+$5.8879981047651824e+26M → SCPS
9	$1,714,064,268,114,722,600,000,000,000,000,000,000	$1,713,434,252,317,512,700,000,000,000,000,000,000.00	$32,637	$2,325.33	+$1.7140642681147225e+30M → SCPS
10	$4,663,521,010,693,878,300,000,000,000,000,000,000,000	$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00	$37,708	$2,786.64	+$4.663521010693878e+33M → SCPS

SCPS vs BTI: Complete Analysis 2026

SCPS — Stock

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Full SCPS Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this SCPS vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCPS vs SCHD SCPS vs JEPI SCPS vs O SCPS vs KO SCPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.